Page 5 - Sosei Group News Today

Sosei Heptares Webinar Presentation for FY2022 Financial Results - read this article along with other careers information, tips and advice on BioSpace

PF-07081532 is the first clinical candidate from multi-target drug discovery collaboration to advance into Phase 2 trialsDosing of first subject in Phase 2...

New agreement leverages Sosei Heptares’ GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and...

TOKYO and CAMBRIDGE, United Kingdom, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G...

/PRNewswire/ -- Global techbio company PrecisionLife, pioneers in precision medicine for chronic diseases, will assess the precision medicine potential of a...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Neurocrine to conduct placebo-controlled Phase 2 study to investigate NBI-1117568 (formerly HTL-0016878) as a potential new treatment for schizophrenia...

New strategic collaboration leverages Sosei Heptares’ StaR® technology and SBDD platform and AbbVie’s extensive neuroscience expertise Second collaboration...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapies...